DAVENPORT & Co LLC Cuts Teva Pharmaceutical Stock Holdings

Institutional investor reduces stake in generic drug maker by over 37%

Mar. 27, 2026 at 8:06am

Got story updates? Submit your updates here. ›

DAVENPORT & Co LLC, an institutional investor, has lowered its position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 37.2% in the 4th quarter, according to the firm's recent Form 13F filing with the Securities & Exchange Commission. The investor now owns 212,737 shares of the company's stock, down from 338,705 shares previously.

Why it matters

Teva Pharmaceutical is one of the world's largest manufacturers of generic medicines, and institutional investor activity in the stock can signal broader market sentiment around the company and the pharmaceutical industry. This reduction in DAVENPORT & Co's stake may indicate a shift in their investment strategy or outlook on Teva's prospects.

The details

According to the 13F filing, DAVENPORT & Co sold 125,968 shares of Teva Pharmaceutical during the fourth quarter, reducing its total position to 212,737 shares valued at $6.64 million. The institutional investor cited unspecified reasons for the stock sale, which represented a 37.2% decrease in its Teva holdings.

  • DAVENPORT & Co LLC filed the 13F report disclosing the stock sale in the 4th quarter of 2026.

The players

DAVENPORT & Co LLC

An institutional investor and asset management firm.

Teva Pharmaceutical Industries Ltd.

An Israeli multinational pharmaceutical company and one of the world's largest manufacturers of generic medicines.

Got photos? Submit your photos here. ›

The takeaway

The reduction in DAVENPORT & Co's Teva Pharmaceutical holdings could signal a broader shift in investor sentiment around the generic drug maker, though the specific reasons behind the sale are unclear from the limited information provided. This change in a major institutional investor's position is worth monitoring for insights into the pharmaceutical industry's outlook.